Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Episurf Medical ABOSTO:EPIS B +1.27% Days Payable is 810.19 as of Mar. 2026, which is 10% above its 10-year median of 737.93. The stock has 7 warning signs investors should review. Among 794 Medical Devices & Instruments companies, Episurf Medical AB ranks better than 95.34% on this metric.
The historical rank and industry rank for Episurf Medical AB's Days Payable or its related term are showing as below:
OSTO:EPIS B'
s Days Payable Range Over the Past 10 Years
Min: 354.26 Med: 737.93 Max: 2080.5
Current: 817.6
During the past 13 years, Episurf Medical AB's highest Days Payable was 2080.50. The lowest was 354.26. And the median was 737.93.
OSTO:EPIS B's Days Payable is ranked better than 95.34% of 794
companies
in the Medical Devices & Instruments industry
Industry Median: 67.85
vs OSTO:EPIS B: 817.60
Episurf Medical AB's Days Payable
increased
from Mar. 2025 (593.13) to Mar. 2026 (810.19).
It may suggest that Episurf Medical ABdelayed paying its suppliers.
Episurf Medical AB Days Payable Related Terms
Episurf Medical AB Days Payable Historical Data
* Premium members only.
The historical data trend for Episurf Medical AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:EPIS B vs ABT, SYK, MDT: Days Payable Comparison
For the Medical Devices subindustry, Episurf Medical AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Episurf Medical AB Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Episurf Medical AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Episurf Medical AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Episurf Medical AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Episurf Medical AB (OSTO:EPIS B) has a Days Payable of 810.19 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Episurf Medical AB and its competitors. This is 10% above median its historical median of 737.93. Over the past decade, Episurf Medical AB's Days Payable has ranged from 354.26 to 2,080.50. According to the industry distribution chart, Episurf Medical AB ranks #37 out of 794 companies in the Medical Devices & Instruments industry, placing it in the top 4.7%.
Is Episurf Medical AB's Days Payable too high?
Episurf Medical AB's current Days Payable of 810.19 is 10% above median its 10-year median of 737.93. Over the past 10 years, this metric has ranged from a low of 354.26 to a high of 2,080.50. The Medical Devices & Instruments industry median Days Payable is 67.85. Episurf Medical AB's value of 810.19 is 1094.1% above this industry median. Based on the distribution chart, Episurf Medical AB ranks #37 out of 794 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Episurf Medical AB's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Episurf Medical AB ranks #37 out of 794 companies for Days Payable. This places Episurf Medical AB in the top 5% of its industry — outperforming the majority of peers. The industry median Days Payable is 67.85. Episurf Medical AB's value of 810.19 is 1094.1% above this benchmark. Historically, Episurf Medical AB's own Days Payable has ranged from 354.26 to 2,080.50 over the past decade. While the company's 10-year median is 737.93 vs. the industry median of 67.85, Episurf Medical AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.85, based on 794 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Episurf Medical AB's current Days Payable of 810.19 is 1094.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Episurf Medical AB and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Episurf Medical AB's current Days Payable is 810.19, which is 10% above median its own 10-year median of 737.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Episurf Medical AB stock overvalued right now?
Based on GuruFocus' analysis, Episurf Medical AB (OSTO:EPIS B) is currently considered Modestly Overvalued. The stock's GF Value™ is kr0.05, compared to a current price of kr0.06 — trading 11.8% above its estimated fair value. The current Days Payable is 810.19, which is 10% above median its 10-year median of 737.93 and 1094.1% above the Medical Devices & Instruments industry median of 67.85. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Episurf Medical AB (OSTO:EPIS B), the current Days Payable is 810.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Episurf Medical AB is a medical device company. The company develops, manufactures, and commercializes solutions for the repair of the local cartilage damage in human joints. Its first patient-specific product portfolio, the knee portfolio, consists of the existing products Episealer Condyle Solo and Episealer Trochlea Solo, Episealer Femoral Twin, Epiguide MOS, and Epioscopy. Episealer Patellofemoral System for the treatment of osteoarthritis limited to thepatellofemoral part of the knee joint. The company is forming a new strategic business segment through the acquisition of real estate assets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:EPIS B has been successfully added to your 
